<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="22091" end="22095" sStart="22009" offset="82" sid="r7.1.use.v.0550" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="Various ligands were added and total RNA was prepared 9 hours later and used for Northern blotting using standard procedures [ 27 ] ." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1478-1336-1-2.anc" start="3111" end="3115" sStart="null" offset="0" sid="null" wn="6" wnkey="show%2:32:02::" annotator="carichter" text="However, different CAR/RXR heterodimer binding sites &lt;b&gt;show&lt;/b&gt; distinct responses to RXR activation." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="1542" end="1550" sStart="null" offset="592" sid="r11.refer.v.0441" wn="7" wnkey="refer%2:32:04::" annotator="adelpriore" text="Initial results showed that CAR is an apparently constitutive transactivator able to activate gene expression in the absence of exogenously added ligands [ 8 9 ] . The first CAR ligands identified, androstanol and androstenol, are inverse agonists that block this constitutive transactivation [ 10 ] . More recently, it has been found that CAR mediates the characteristic response of a subset of drug metabolizing enzymes to a variety of structurally unrelated foreign compounds [ 11 ] . These xenobiotic activators are referred to as &quot;phenobarbital (PB) - like,&quot; based on the prototypic effects of the anti-epileptic agent on drug metabolism [ 12 13 14 ] . The most potent activator of murine CAR is the high affinity agonist ligand TCPOBOP (1,4-bis [2-(3,5-dichloropyridyloxy)]benzene) [ 15 16 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="432" end="438" sStart="null" offset="389" sid="r8.number.n.0849" wn="1" wnkey="number%1:07:00::" annotator="veweser" text="At least one third of the 48 human members of the nuclear hormone receptor superfamily function as heterodimers with the Retinoid X Receptors, (RXRs, NR2B1-3) [ 1 ] . Some, but not all of these heterodimers can be directly activated by RXR agonists, called rexinoids, which include the endogenous ligand 9-cis-retinoic acid (9-cis-RA) and a number of synthetic compounds." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="1751" end="1755" sStart="null" offset="811" sid="r10.high.j.0799" wn="1" wnkey="high%3:00:02::" annotator="cgozo" text="Initial results showed that CAR is an apparently constitutive transactivator able to activate gene expression in the absence of exogenously added ligands [ 8 9 ] . The first CAR ligands identified, androstanol and androstenol, are inverse agonists that block this constitutive transactivation [ 10 ] . More recently, it has been found that CAR mediates the characteristic response of a subset of drug metabolizing enzymes to a variety of structurally unrelated foreign compounds [ 11 ] . These xenobiotic activators are referred to as &quot;phenobarbital (PB) - like,&quot; based on the prototypic effects of the anti-epileptic agent on drug metabolism [ 12 13 14 ] . The most potent activator of murine CAR is the high affinity agonist ligand TCPOBOP (1,4-bis [2-(3,5-dichloropyridyloxy)]benzene) [ 15 16 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="138" end="146" sStart="null" offset="95" sid="r11.function.n.0497" wn="2147483645" wnkey="null" annotator="anfahmy" text="At least one third of the 48 human members of the nuclear hormone receptor superfamily function as heterodimers with the Retinoid X Receptors, (RXRs, NR2B1-3) [ 1 ] . Some, but not all of these heterodimers can be directly activated by RXR agonists, called rexinoids, which include the endogenous ligand 9-cis-retinoic acid (9-cis-RA) and a number of synthetic compounds." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="20052" end="20056" sStart="null" offset="466" sid="r9.full.j.0426" wn="2" wnkey="full%5:00:01:whole:00" annotator="anfahmy" text="The ?RARE-TK-Luc reporter plasmid with three copies of the DR-5 motif from the promoter of the mouse RAR?2 gene has been described previously, as has the CYP2B10-TK-Luc reporter with two copies of the DR-4 type elements from the promoter of the mouse CYP2B10 gene and the CYP3A4-TK-luc reporter with three copies of the ER-6 element from the human CYP3A4 promoter [ 16 ] . Expression vectors for full length mCAR and RXR proteins were as described [ 9 ] . The cdm8-mCAR?8 deletion construct containing a deletion of the last 8 amino acids and the mutant with 2 helix 3 mutations (F171L, I174A) that block ligand binding and response have been described previously [ 16 ] , as has the cdm8-RXR?19 construct with a deletion of the last 19 amino acids [ 3 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="13561" end="13572" sStart="null" offset="161" sid="r11.combination.n.0043" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Finally, expression of the endogenous CYP2B6 gene in CAR expressing HepG2 cells is modestly inhibited by LG1069 alone, androstanol alone and the combination of both." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="4214" end="4225" sStart="null" offset="154" sid="r11.combination.n.0312" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="An increase in the mobility of the CAR/RXR complex was also observed in the presence of TCPOBOP or androstanol, alone or in combination with 9-cis RA (data not shown)." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="13561" end="13572" sStart="null" offset="161" sid="r11.combination.n.0043" wn="1" wnkey="combination%1:14:00::" annotator="adelpriore" text="Finally, expression of the endogenous CYP2B6 gene in CAR expressing HepG2 cells is modestly inhibited by LG1069 alone, androstanol alone and the combination of both." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1478-1336-1-2.anc" start="1106" end="1111" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" annotator="cgozo" text="Initial results showed that CAR is an apparently constitutive transactivator able to activate gene expression in the absence of exogenously &lt;b&gt;added&lt;/b&gt; ligands [ 8 9 ] . The first CAR ligands identified, androstanol and androstenol, are inverse agonists that block this constitutive transactivation [ 10 ] . More recently, it has been found that CAR mediates the characteristic response of a subset of drug metabolizing enzymes to a variety of structurally unrelated foreign compounds [ 11 ] . These xenobiotic activators are referred to as &quot;phenobarbital (PB) - like,&quot; based on the prototypic effects of the anti-epileptic agent on drug metabolism [ 12 13 14 ] . The most potent activator of murine CAR is the high affinity agonist ligand TCPOBOP (1,4-bis [2-(3,5-dichloropyridyloxy)]benzene) [ 15 16 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1478-1336-1-2.anc" start="17758" end="17761" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" annotator="brubin" text="Overall, we conclude that the disparate effects of rexinoids on CAR/RXR heterodimers in different contexts &lt;b&gt;add&lt;/b&gt; significantly to the potential complexity of the effects of RXR ligands on such nuclear receptor heterodimers, and demonstrate that classifying a particular complex as permissive or non-permissive can be an oversimplification." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="16041" end="16048" sStart="null" offset="140" sid="null" wn="2" wnkey="absence%1:04:00::" annotator="vebatchelder" text="On the ?RARE, for example, the RXR agonist might bind, but not increase transactivation beyond that observed in the absence of ligands." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="11813" end="11820" sStart="null" offset="24" sid="r11.absence.n.0517" wn="1" wnkey="absence%1:26:00::" annotator="vebatchelder" text="In vitro studies in the absence of DNA demonstrate that CAR/RXR heterodimers can be activated by an agonist ligand for either receptor." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="16041" end="16048" sStart="null" offset="140" sid="null" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="On the ?RARE, for example, the RXR agonist might bind, but not increase transactivation beyond that observed in the absence of ligands." />
    <s path="[OANC]/data/written_2/technical/biomed/1478-1336-1-2.anc" start="15587" end="15594" sStart="null" offset="209" sid="r11.absence.n.0539" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="Some precedence for a significant allosteric effect of one heterodimer partner on another is provided by the inability of the insect ecdysone receptor to bind its steroid ligand in the absence of its heterodimer partner USP [ 21 ] ." />
  </sentences>
</list>